{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:07Z","timestamp":1740107047094,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Infection of lymphocytes with the Epstein-Barr virus (EBV) is a well-documented risk factor for developing lymphoma. The incidence of EBV positivity in lymphoma depends on the subtype and can range from 10% in diffuse large B-cell lymphoma (DLBCL) to 100% in endemic Burkitt lymphoma (BL), (Shannon-Lowe and Rickinson, Front Oncol 9:713, 2019). However, in most cases, EBV infection remains unnoticed until diagnosis of lymphoma is made. EBV seropositivity is present in\u2009&gt;\u200990% of the world\u2019s population. Although mostly asymptomatic, in some cases, EBV can cause clinical symptoms, the most common of which are fever, lymphadenopathy and pharyngitis in infectious mononucleosis. Less common presentations include lymphomatoid granulomatosis and mucocutaneous ulcer. Here we report two cases of patients, who were initially diagnosed with localized EBV infection and reactive B-cell proliferation. After B-cell-directed treatment, both patients developed overt lymphoma, in one case classical Hodgkin\u2019s lymphoma (cHL) and in the other case angioimmunoblastic T-cell lymphoma (AITL).<\/jats:p>","DOI":"10.1007\/s00432-022-04145-4","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T18:02:52Z","timestamp":1655920972000},"page":"2929-2932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two cases of EBV infection preceding lymphoma"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-2947","authenticated-orcid":false,"given":"Jonas","family":"Saal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Busher","family":"Aboudan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-9880","authenticated-orcid":false,"given":"Annkristin","family":"Heine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"4145_CR1","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1200\/jco.2012.43.3797","volume":"31","author":"AR Huppmann","year":"2012","unstructured":"Huppmann AR, Roullet MR, Raffeld M, Jaffe ES (2012) Angioimmunoblastic T-cell lymphoma partially obscured by an epstein-barr virus-negative clonal plasma cell proliferation. J Clin Oncol 31:e28\u2013e30. https:\/\/doi.org\/10.1200\/jco.2012.43.3797","journal-title":"J Clin Oncol"},{"key":"4145_CR2","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1200\/jco.2010.28.15_suppl.8049","volume":"28","author":"B Joly","year":"2010","unstructured":"Joly B, Plonquet A, Grare M et al (2010) Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: results of the phase II RAIL trial\u2014a prospective study of the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). J Clin Oncol 28:8049\u20138049. https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.8049","journal-title":"J Clin Oncol"},{"key":"4145_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A (2019) The global landscape of EBV-associated tumors. Front Oncol 9:713. https:\/\/doi.org\/10.3389\/fonc.2019.00713","journal-title":"Front Oncol"},{"key":"4145_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","volume":"138","author":"K Willenbrock","year":"2007","unstructured":"Willenbrock K, Br\u00e4uninger A, Hansmann M (2007) Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 138:733\u2013739. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06725.x","journal-title":"Br J Haematol"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1746-1596-7-7","volume":"7","author":"Q-X Yang","year":"2012","unstructured":"Yang Q-X, Pei X-J, Tian X-Y et al (2012) Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature. Diagn Pathol 7:7. https:\/\/doi.org\/10.1186\/1746-1596-7-7","journal-title":"Diagn Pathol"},{"key":"4145_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2141.2007.06620.x","volume":"138","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Attygalle AD, Chuang S et al (2007) Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 138:44\u201353. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06620.x","journal-title":"Br J Haematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04145-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04145-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04145-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:21:14Z","timestamp":1663057274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04145-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":6,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04145-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest concerning the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}